暗盘资金流向曝光！提前捕捉庄家建仓信号>> 创新药板块短线拉升，海南海药（000566）、哈三联（002900）、华森制药（002907）涨停，睿智医药 （300149）、诺思兰德涨超10%，舒泰神（300204）、海创药业、三元基因、梓橦宫、热景生物等跟 涨。 ...

Group 1 - The core point of the article is the significant stock price increases of several pharmaceutical companies following the approval of 11 innovative drugs by the National Medical Products Administration on May 29 [1] Group 2 - Harbin Pharmaceutical Group (哈三联) reached the daily limit increase in stock price [1] - Companies such as Ruizhi Pharmaceutical (睿智医药), Xinnowei (新诺威), Hainan Haiyao (海南海药), and Huasen Pharmaceutical (华森制药) saw stock price increases of over 5% [1] - Other companies including Fosun Pharma (复星医药), Yipinhong (一品红), Haiwang Biological (海王生物), and Northeast Pharmaceutical (东北制药) also experienced stock price increases [1]

Group 1: Robotics and AI Development in Zhuhai - Zhuhai government offers up to 30 million yuan in funding for key core technology breakthroughs in robotics [1] - The policy encourages the establishment of innovation centers and provides up to 10 million yuan for robot data training facilities [1] - Zhuhai aims to accelerate the construction of an AI and robotics industry hub, potentially becoming a demonstration window for technological innovation in the Greater Bay Area [1] Group 2: Development of Northern Metropolis in Hong Kong - Hong Kong Chief Executive John Lee expresses urgency in accelerating the development of the Northern Metropolis [2] - Discussions with legislators focus on attracting businesses, enhancing interaction with mainland China, and construction progress [2] - The Northern Metropolis is seen as a new engine for economic growth in Hong Kong through deepening cooperation in science and technology with Shenzhen [2] Group 3: Tourism Growth in Macau - Macau's inbound tourist numbers in April increased by 12.1% year-on-year to 204,000 [3] - Hotel occupancy rates rose by 4.7 percentage points to 87.8%, with guest numbers increasing by 3.4% to 1.199 million [3] - The average length of stay remained stable at 1.6 nights, indicating positive trends in the tourism sector [3][4] Group 4: Agricultural Developments in Shenzhen - In Shenzhen, 99 century-old lychee trees were successfully auctioned for harvesting rights and naming rights [5] - The lychee planting area in Nanshan District is 22,500 acres, with an estimated production of 5,000 tons this year [5] - Bidders gain multiple benefits, including economic and cultural rights, enhancing the value of agricultural products [5] Group 5: Shenzhen Stock Market Performance - Shenzhen Component Index closed at 10,127.20 points, up 1.24% [6] - Notable gainers include N Guqi with a 164.90% increase and Tian Sheng New Materials with a 20.06% rise [7] - Decliners include Yiju Energy down 10.00% and Yong'an Pharmaceutical down 9.99% [7]

Group 1 - The innovative drug sector in A-shares has shown a strong comeback, with multiple stocks experiencing significant price increases, including Shuyou Shen (20% increase) and Ruizhi Pharmaceutical (20% increase), indicating a bullish market sentiment [1] - The Hong Kong market also saw a rise, with WuXi AppTec increasing by 19.88% and several innovative drug ETFs in Hong Kong showing year-to-date gains exceeding 40%, outperforming similar products [1][2] - Analysts suggest that the domestic market is entering a concentrated listing period for innovative drugs, supported by comprehensive policy backing and improvements in commercial medical insurance, which are expected to enhance the commercialization process beyond market expectations [1][5] Group 2 - There is a noticeable divergence in the performance of various medical ETFs, with some experiencing significant inflows while others face substantial outflows, indicating mixed investor sentiment [2][3] - The top-performing innovative drug ETFs, such as ICBC Hong Kong Innovative Drug ETF and Huatai-PineBridge Hong Kong Innovative Drug ETF, have seen net inflows of 2.43 billion and 2.31 billion respectively, while the E Fund CSI 300 Healthcare ETF has recorded the highest net outflow of 2.5 billion [3] - The medical sector is expected to show its best performance in three years by mid-2025, driven by policy optimization and AI industry empowerment, with a clear trend of performance and valuation recovery anticipated in the second half of the year [3] Group 3 - The innovative drug sector has rebounded significantly after a period of decline, with innovative drug ETFs showing substantial weekly gains, particularly in the lead-up to the ASCO annual meeting, which has heightened industry interest [4] - The upcoming ASCO meeting is expected to showcase numerous original research results from Chinese pharmaceutical companies, indicating a shift towards international innovation in drug development [4][5] - Recent approvals of six domestic innovative drugs in May across critical treatment areas such as diabetes and tumors have injected strong momentum into the pharmaceutical industry [5]

作者 | 哥吉拉 数据支持 | 勾股大数 据（www.gogudata.com） 5月29日，A股主要指数高开高走，截至收盘，沪指涨0.7%报3363点，深证成指涨1.24%，创业板指涨1.37%。全市场近4500股上涨，逾百 股涨停。 板块方面，金融科技、创新药、互联网、半导体等热门板块表现强势，市场情绪相比近日明显提振。 其中，创新药是涨幅最明显的板块之一，睿智医药、舒泰神、益方生物强势斩获20CM涨停，另有十多家医药股涨幅均超过10%，堪称又一轮 暴涨潮。 | 代码 | 名称 | 现价 | 1 9 mm a lond a rither more an a many 143 1994 (310 1 涨跌幅▼ | 年初至今涨跌幅 | 总市值1 | | --- | --- | --- | --- | --- | --- | | 300149 | 睿智医药 | 8.56 c | 20.06% | 33.33% | 43亿 | | 300204 | 舒泰神 | 23.04 c | 20.00% | 210.93% | 110亿 | | 688382 | 益元生物-U | 29.10 c | 20.00% | 11 ...

Market Overview - A-shares experienced a strong rally with major indices rising, including the Shenzhen Component Index and the ChiNext Index, both up over 1% [1] - The North Stock 50 Index surged nearly 3%, with total trading volume across the Shanghai, Shenzhen, and North exchanges reaching 12,136 billion yuan, an increase of nearly 1,800 billion yuan from the previous day [1] Semiconductor Sector - The semiconductor sector saw significant gains, with stocks like Gaoneng Electronics and Guangliwei hitting the 20% limit up [3][4] - Other notable performers included Huada Jiutian, which rose nearly 15%, and Taiji Co., which increased over 9% [3] Innovative Drug Concept - The innovative drug sector experienced a substantial increase, with companies like Ruizhi Pharmaceutical, Yifang Biotechnology, and Shutaishen all reaching the 20% limit up [7][8] - Changshan Pharmaceutical also saw a rise of over 15%, marking a new high [7] Data Element Concept - The data element concept showed strong performance, with stocks such as Lakala, Xiongdi Technology, and Wanma Technology all hitting the 20% limit up [10][11] - The National Bureau of Statistics announced the launch of the "Data Element ×" competition, aimed at promoting the use of public and enterprise data to create new application scenarios [12] Regulatory Environment - Reports indicated that the U.S. International Trade Court has suspended the implementation of a tariff policy announced by the Trump administration, which may impact various sectors including technology and pharmaceuticals [2]

Market Overview - The A-share market saw a strong rise with the three major indices up, including the Shanghai Composite Index increasing by 0.7% to 3363.45 points, the Shenzhen Component rising by 1.24% to 10127.2 points, and the ChiNext Index up by 1.37% to 2012.55 points. The North Star 50 Index surged by 2.73% [1] - Total trading volume in the Shanghai, Shenzhen, and North exchanges reached 121.36 billion yuan, an increase of nearly 18 billion yuan compared to the previous day [1] Semiconductor Sector - The semiconductor sector experienced a significant rally, with stocks like GCL-Poly and Guangliwei both hitting the 20% limit up. Other notable performers included Huada Jiutian, which rose nearly 15%, and Taiji Co., which increased over 9% [5][6] - Reports indicated that the U.S. government is requesting local companies to stop exporting software related to semiconductor design technology to China, affecting major companies in the Electronic Design Automation (EDA) market [7] Innovative Drug Sector - The innovative drug concept saw a substantial increase, with stocks such as Ruizhi Pharmaceutical, Yifang Bio, and Shutaishen all hitting the 20% limit up. Changshan Pharmaceutical rose over 15%, reaching new highs [9][11] - Shutaishen announced that it received approval for clinical trials of its STSA-1002 injection for acute respiratory distress syndrome (ARDS), marking a significant step in its drug development [12] Data Element Sector - The data element concept showed strong performance, with stocks like Lakala, Xiongdi Technology, and Tianyang Technology all hitting the 20% limit up. Youbuxun rose over 14% [15][16] - The National Data Bureau announced the launch of the "Data Element ×" competition aimed at promoting the use of public and enterprise data, which is expected to enhance the economic and social development through better data application [17]

Group 1 - The U.S. International Trade Court has suspended the Trump administration's comprehensive tariff policy, which was announced on April 2, 2023, citing that the President does not have the constitutional authority to impose such tariffs on nearly all trading partners [4][5]. - The court's ruling allows the administration a maximum of 10 days to halt the imposition of tariffs, following a lawsuit filed by a coalition of 12 states claiming the tariffs were an unlawful exercise of power [5][6]. Group 2 - EDA (Electronic Design Automation) concept stocks in the A-share market have surged, with companies like Guangliwei and Gai Lun Electronics hitting the 20% limit-up, indicating strong market interest in this sector [6][7]. - The global EDA market is dominated by U.S. companies, with Synopsys, Cadence, and Siemens EDA holding a combined market share of 74%, and these companies also control about 80% of the Chinese EDA market [10]. - The Trump administration's recent actions to restrict U.S. companies from selling semiconductor design software to Chinese firms are expected to impact the EDA market dynamics [10]. Group 3 - The pharmaceutical sector has seen a significant rally, with stocks like Shuyou Shen and WuXi AppTec experiencing substantial gains, driven by positive clinical trial results and upcoming major conferences [11][12]. - Shuyou Shen's STSA-1002 injection showed promising results in a clinical trial for ARDS, with mortality rates significantly lower than the control group, which has attracted investor attention [16]. - The ASCO (American Society of Clinical Oncology) annual meeting is set to showcase numerous original research projects from Chinese researchers, highlighting advancements in domestic drug development and increasing competitiveness in the global market [16][17].

A股CRO概念股午后走强，昭衍新药涨停，睿智医药、联化科技此前封板，美迪西涨超10%，凯莱英、 康龙化成、诺思格、药明康德等跟涨。 ...

Market Overview - The A-share market experienced a rebound on May 29, with the ChiNext index leading the gains. The Shanghai Composite Index rose by 0.72%, the Shenzhen Component Index increased by 1.12%, and the ChiNext index gained 1.16%. The total trading volume in the Shanghai and Shenzhen markets reached 743.7 billion yuan, an increase of 91.3 billion yuan compared to the previous trading day. Over 4,400 stocks in the market saw an increase [1]. Sector Performance - Sectors such as unmanned vehicles, digital currency, complete automobiles, and innovative drugs showed significant gains, while sectors like glyphosate, gold, food, and liquor experienced declines [2]. Unmanned Vehicle Sector - The "unmanned driving" concept continued to be active, with several stocks hitting the daily limit. Notable performers included Yunnei Power, Qiming Information, Hexing Shares, and others, with Yunnei Power achieving five consecutive trading limit increases over seven days. The sector is benefiting from supportive policies and capital investments, with the Ministry of Transport planning to expedite the implementation of AI in transportation [5][7]. - The market potential for unmanned delivery vehicles is substantial, estimated at approximately 468 billion yuan, based on the number of logistics points across the country. The delivery volume for leading unmanned delivery vehicle manufacturers is expected to reach tens of thousands by 2025 [7]. Innovative Drug Sector - The CRO (Contract Research Organization) concept also saw strong performance, with stocks like Ruizhi Medicine and Lianhua Technology hitting the daily limit. The innovative drug sector is gaining traction, with several companies set to showcase their research results at the upcoming ASCO annual meeting. The collaboration between domestic companies and global firms is expected to enhance the integration of Chinese innovative drugs into the global supply chain [8].